US Broker Ratings

Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Exploring a 65.75% Potential Upside in the Biotech Sector

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) has captured the attention of investors with its ambitious strides in the biotechnology sector. With a market capitalization of $1.05 billion, this clinical-stage biopharmaceutical company..

Organogenesis Holdings Inc. (ORGO) Stock Analysis: Exploring a 58.73% Potential Upside

Individual investors seeking opportunities in the healthcare sector, particularly in regenerative medicine, may find Organogenesis Holdings Inc. (NASDAQ: ORGO) an intriguing prospect. This Massachusetts-based company specializes in developing, manufacturing, and..

AngioDynamics, Inc. (ANGO) Investor Outlook: A 66% Potential Upside Amidst Healthcare Innovation

AngioDynamics, Inc. (NASDAQ: ANGO), a prominent player in the healthcare sector, specializes in the design and manufacturing of advanced medical, surgical, and diagnostic devices. With a focus on treating peripheral..

Treace Medical Concepts, Inc. (TMCI): Investor Outlook with a 15% Upside Potential Amid Revenue Growth

Treace Medical Concepts, Inc. (NASDAQ: TMCI), a key player in the healthcare sector specializing in medical devices, is drawing attention with its innovative solutions for bunion and midfoot deformities. Founded..

Precigen, Inc. (PGEN) Stock Analysis: Unveiling a 99% Upside Potential

In the ever-evolving landscape of biotechnology, Precigen, Inc. (NASDAQ: PGEN) has emerged as a notable player, captivating investor interest with its innovative approach to gene and cell therapies. As a..

Myriad Genetics (MYGN) Stock Analysis: Navigating Earnings Challenges and Market Opportunities

Myriad Genetics, Inc. (NASDAQ: MYGN) operates at the intersection of molecular diagnostics and precision medicine, offering an extensive array of genetic testing services. Despite its innovative portfolio, Myriad’s financial performance..

Altimmune, Inc. (ALT) Stock Analysis: Exploring a 366% Potential Upside in Biotech Innovation

Altimmune, Inc. (NASDAQ: ALT), a clinical-stage biopharmaceutical company, stands at a fascinating juncture with a compelling potential upside of 366.12%. As a player in the biotechnology sector, Altimmune focuses on..

Oruka Therapeutics, Inc. (ORKA)

⚠️ No article content returned.

..

Sonida Senior Living, Inc. (SNDA) Stock Analysis: Navigating Challenges in the Healthcare Sector

Sonida Senior Living, Inc. (NASDAQ: SNDA), a prominent player in the healthcare sector, operates senior housing communities across the United States. With a market capitalization of $490.34 million, the company..

Prothena Corporation plc (PRTA) Stock Analysis: Exploring a 42% Upside Potential in Biotech Innovation

Prothena Corporation plc (NASDAQ: PRTA) is carving a niche for itself in the biotechnology sector with a focus on innovative therapies for diseases caused by protein dysregulation. Based in Dublin,..

SIGA Technologies Inc. (SIGA): Investor Outlook on a High-Growth Pharma Player with Robust Revenue Surge

SIGA Technologies Inc. (NASDAQ: SIGA), a noteworthy player in the healthcare sector, is capturing investor attention with its remarkable revenue growth. As a commercial-stage pharmaceutical company, SIGA specializes in the..

Rapport Therapeutics, Inc. (RAPP) Stock Report: Exploring a 130% Potential Upside in the Biotech Arena

Rapport Therapeutics, Inc. (RAPP) is a promising player in the biotechnology industry, focusing on developing groundbreaking small molecule medicines to address central nervous system (CNS) disorders. With a market capitalization..

Enhabit, Inc. (EHAB) Stock Analysis: Exploring a 15.6% Potential Upside in the Healthcare Sector

Investors looking for opportunities in the healthcare sector might find Enhabit, Inc. (EHAB) an intriguing prospect. As a provider of home health and hospice services in the United States, Enhabit..

Auna SA (AUNA) Stock Analysis: Healthcare Play with Nearly 90% Upside Potential

Auna SA (AUNA), a healthcare service provider headquartered in Luxembourg, is attracting keen interest from investors due to its significant upside potential. With operations spanning hospitals and clinics in Mexico,..

Autolus Therapeutics (AUTL) Investor Outlook: A 573% Potential Upside in T Cell Therapy

Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company based in the United Kingdom, is garnering significant attention in the biotechnology sector. With a market capitalization of $380.58 million, the..

Butterfly Network, Inc. (BFLY) Stock Analysis: A Promising 104.30% Upside Potential for Healthcare Innovators

Butterfly Network, Inc. (NASDAQ: BFLY) is carving out a niche in the healthcare sector with its innovative approach to ultrasound imaging solutions. With a market capitalization of $390.2 million, this..

EyePoint Pharmaceuticals, Inc. (EYPT) Stock Analysis: Exploring a 158% Potential Upside in Retinal Therapeutics

Investors with a keen eye on the biotechnology sector should pay close attention to EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a promising player in the healthcare industry with a focus on..

Inventiva S.A. (IVA) Stock Analysis: Unveiling a 143% Potential Upside in the Booming Biotechnology Sector

Investors with a keen eye on the biotechnology sector might find Inventiva S.A. (IVA) an intriguing prospect, especially given the stock’s potential upside of 143.15%. Operating out of Daix, France,..

Fortrea Holdings Inc. (FTRE) Stock Analysis: Navigating the Biotech Terrain with a 7.20% Revenue Growth

Fortrea Holdings Inc. (FTRE), a contract research organization based in Durham, North Carolina, is making waves in the biotechnology sector. Specializing in biopharmaceutical product and medical device development solutions, the..

Surmodics, Inc. (SRDX) Stock Analysis: Navigating Challenges in the Medical Device Sector

Surmodics, Inc. (SRDX), a notable player in the healthcare sector specializing in medical devices, presents a complex investment narrative influenced by current market dynamics and performance metrics. With a market..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds